<DOC>
	<DOCNO>NCT02368717</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety 4-week double-blind treatment PENTASA enema compare placebo enema Chinese patient mild moderate active left-sided ulcerative colitis , follow maximal 28-week open-label extension phase PENTASA enema and/or PENTASA tablet .</brief_summary>
	<brief_title>An Efficacy Safety Study PENTASA Chinese Patients With Left-sided Active Ulcerative Colitis Followed 24-Week Open-Label Extension Phase</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Newly diagnose recurrent mild moderate leftsided active ulcerative colitis Mayo score least 4 great 10 point score ≥ 2 colonoscopy Extent colonic involvement endoscopy subscore Mayo score confirm colonoscopy The patient compliant Patient Daily Diary adequately respond question ≥5 recent full 7 day Randomization Visit Negative stool test screening rule parasites bacterial pathogen Patients receive &gt; 2g/day oral 5aminosalicylic acid ( 5ASA ) product , receive topical rectal 5ASA &gt; 3g/week , within 7 day prior screen Severe/fulminant ulcerative colitis toxic dilatation colon Prior bowel resection surgery Patients allergic 5ASA derivative , excipients , aspirin , salicylates Patients one diseases : bacillary dysentery , amebic dysentery , chronic schistosomiasis , intestinal tuberculosis Crohn 's disease Patients unable fill Patient Daily Diary follow datacapturing procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>